{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:29:12Z","timestamp":1769524152084,"version":"3.49.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,2,23]],"date-time":"2012-02-23T00:00:00Z","timestamp":1329955200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurotox Res"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s12640-012-9314-y","type":"journal-article","created":{"date-parts":[[2012,2,22]],"date-time":"2012-02-22T14:08:20Z","timestamp":1329919700000},"page":"265-273","source":"Crossref","is-referenced-by-count":57,"title":["Efficacy and Safety of Long-term Botulinum Toxin Treatment in Craniocervical Dystonia: A Systematic Review"],"prefix":"10.1007","volume":"22","author":[{"given":"Carlo","family":"Colosimo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorina","family":"Tiple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Berardelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,23]]},"reference":[{"key":"9314_CR1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF03033927","volume":"9","author":"G Abbruzzese","year":"2006","unstructured":"Abbruzzese G, Berardelli A (2006) Neurophysiological effects of botulinum toxin type A. Neurotoxic Res 9:109\u2013114","journal-title":"Neurotoxic Res"},{"key":"9314_CR2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.toxicon.2009.02.003","volume":"54","author":"A Albanese","year":"2009","unstructured":"Albanese A (2009) Discussion of unique properties of botulinum toxins. Toxicon 54:702\u2013708","journal-title":"Toxicon"},{"key":"9314_CR3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","volume":"18","author":"A Albanese","year":"2011","unstructured":"Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, Gasser T, Krauss JK, Nardocci N, Newton A, Valls-Sol\u00e9 J (2011) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 18:5\u201318","journal-title":"Eur J Neurol"},{"key":"9314_CR4","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1002\/mds.20020","volume":"19","author":"MZ Atassi","year":"2004","unstructured":"Atassi MZ (2004) Basic immunological aspects of botulinum toxin therapy. Mov Disord 19:S68\u2013S84","journal-title":"Mov Disord"},{"key":"9314_CR5","first-page":"219","volume":"19","author":"MZ Atassi","year":"1999","unstructured":"Atassi MZ, Oshima M (1999) Structure, activity and immune recognition of botulinum neurotoxins. Crit Rev Immunol 19:219\u2013260","journal-title":"Crit Rev Immunol"},{"key":"9314_CR6","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/jnnp.72.5.608","volume":"72","author":"Y Ben-Shlomo","year":"2002","unstructured":"Ben-Shlomo Y, Camfield L, Warner T, On behalf of the ESDE Collaborative Group (2002) What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry 72:608\u2013614","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9314_CR7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12640-009-9023-3","volume":"15","author":"AR Bentivoglio","year":"2009","unstructured":"Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A (2009) Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotoxic Res 15:224\u2013231","journal-title":"Neurotoxic Res"},{"key":"9314_CR8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/mds.20290","volume":"20","author":"B Berman","year":"2005","unstructured":"Berman B, Seeberger L, Kumar R (2005) Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia. Mov Disord 20:233\u2013237","journal-title":"Mov Disord"},{"key":"9314_CR9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1468-1331.2010.03047.x","volume":"17","author":"A Blitzer","year":"2010","unstructured":"Blitzer A (2010) Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series. Eur J Neurol 17:28\u201330","journal-title":"Eur J Neurol"},{"key":"9314_CR10","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00005537-199810000-00003","volume":"108","author":"A Blitzer","year":"1998","unstructured":"Blitzer A, Brin MF, Stewart CF (1998) Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 108:1435\u20131441","journal-title":"Laryngoscope"},{"key":"9314_CR11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.46.1.26","volume":"46","author":"G Borodic","year":"1996","unstructured":"Borodic G, Johnson E, Goodnough M, Schantz E (1996) Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 46:26\u201329","journal-title":"Neurology"},{"key":"9314_CR12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1468-1331.2004.00867.x","volume":"11","author":"M Brainin","year":"2004","unstructured":"Brainin M, Barnes M, Baron J-C, Gilhus NE, Hughes R, Selmaj K, Waldemar G (2004) Guidance for the preparation of neurological management guidelines by EFNS scientific task forces\u2014revised recommendations 2004. Eur J Neurol 11:577\u2013581","journal-title":"Eur J Neurol"},{"key":"9314_CR13","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1212\/WNL.50.5.1461","volume":"50","author":"JWM Brans","year":"1998","unstructured":"Brans JWM, Lindeboom R, Aramideh M, Speelman JD (1998) Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia. Neurology 50:1461\u20131463","journal-title":"Neurology"},{"key":"9314_CR14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF02850184","volume":"22","author":"A Brashear","year":"2005","unstructured":"Brashear A, Hogan P, Wooten-Watts M, Marchetti A, Magar R, Martin J (2005) Longitudinal assessment of the dose consistency of botulinum toxin type A (Botox) for cervical dystonia. Adv Ther 22:49\u201355","journal-title":"Adv Ther"},{"key":"9314_CR15","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1002\/(SICI)1097-4598(1997)6+<146::AID-MUS10>3.0.CO;2-4","volume":"6","author":"MF Brin","year":"1997","unstructured":"Brin MF (1997) Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 6:S146\u2013S168","journal-title":"Muscle Nerve"},{"issue":"7","key":"9314_CR16","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","volume":"53","author":"M Brin","year":"1999","unstructured":"Brin M, Lew M, Adler C et al (1999) Safety and efficacy of Neurobloc (botulinum toxin type B) in type A resistant cervical dystonia. Neurology 53(7):1431\u20131438","journal-title":"Neurology"},{"key":"9314_CR17","first-page":"93","volume-title":"Dystonia: etiology, clinical features, and treatment","author":"MF Brin","year":"2004","unstructured":"Brin MF, Aoki KR, Dressler D (2004) Pharmacology of botulinum toxin therapy. In: Brin MF, Comella C (eds) Dystonia: etiology, clinical features, and treatment. Lippincott Williams & Wilkins, Philadelphia, pp 93\u2013112"},{"key":"9314_CR18","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","volume":"23","author":"MF Brin","year":"2008","unstructured":"Brin MF, Comella CL, Jankovic J (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23:1353\u20131360","journal-title":"Mov Disord"},{"key":"9314_CR19","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/brain\/121.5.977","volume":"121","author":"ML Byrnes","year":"1998","unstructured":"Byrnes ML, Thickbroom GW, Wilson SA et al (1998) The corticomotor representation of upper limb muscles in writer\u2019s cramp and changes following botulinum toxin injection. Brain 121:977\u2013988","journal-title":"Brain"},{"key":"9314_CR20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/112067210301300401","volume":"13","author":"P Calace","year":"2003","unstructured":"Calace P, Cortese G, Piscopo R et al (2003) Treatment of blepharospasm with botulinum neurotoxin type A: long-term results. Eur J Ophtalmol 13:331\u2013336","journal-title":"Eur J Ophtalmol"},{"key":"9314_CR21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1471-4159.2009.05887.x","volume":"109","author":"M Caleo","year":"2009","unstructured":"Caleo M, Antonucci F, Restani L, Mazzocchio R (2009) A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism? J Neurochem 109:15\u201324","journal-title":"J Neurochem"},{"key":"9314_CR22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1590\/S0004-282X2011000600004","volume":"69","author":"CH Camargo","year":"2011","unstructured":"Camargo CH, Teive HA, Becker N, Munhoz RP, Werneck LC (2011) Botulinum toxin type A and cervical dystonia: a seven-year follow-up. Arq Neuropsiquiatr 69:745\u2013750","journal-title":"Arq Neuropsiquiatr"},{"key":"9314_CR23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/brain\/120.4.571","volume":"120","author":"AO Ceballos-Baumann","year":"1997","unstructured":"Ceballos-Baumann AO, Sheean G, Passingham RE, Mardsen CD, Brooks DJ (1997) Botulinum toxin does not reverse the cortical dysfunction associated with writer\u2019s cramp. A PET study. Brain 120:571\u2013582","journal-title":"Brain"},{"key":"9314_CR24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.870060206","volume":"6","author":"J Chan","year":"1991","unstructured":"Chan J, Brin MF, Fahn S (1991) Idiopathic cervical dystonia: clinical characteristics. Mov Disord 6:119\u2013126","journal-title":"Mov Disord"},{"issue":"7","key":"9314_CR25","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.clinthera.2007.07.020","volume":"29","author":"MA Chapman","year":"2007","unstructured":"Chapman MA, Barron R, Tanis DC et al (2007) Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 29(7):1325\u20131337","journal-title":"Clin Ther"},{"key":"9314_CR26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/eye.2009.192","volume":"24","author":"S Cillino","year":"2010","unstructured":"Cillino S, Raimondi G, Gu\u00e9pratte N et al (2010) Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes. Eye 24:600\u2013607","journal-title":"Eye"},{"key":"9314_CR27","doi-asserted-by":"crossref","unstructured":"Colosimo C, Berardelli A (2011) Clinical phenomenology of dystonia. In: Brotchie J, Bezard E, Jenner P (eds) International Review of Neurobiology, vol 98. pp 509\u2013524","DOI":"10.1016\/B978-0-12-381328-2.00018-3"},{"key":"9314_CR28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1017\/CBO9780511575761.009","volume-title":"Manual of Botulinum toxin therapy","author":"C Colosimo","year":"2009","unstructured":"Colosimo C, Tiple D, Berardelli A (2009) Treatment of blepharospasm. In: Truong D, Hallett M, Dressler D (eds) Manual of Botulinum toxin therapy. Cambridge University Press, Cambridge, pp 49\u201353"},{"issue":"Suppl 1","key":"9314_CR29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1468-1331.2010.03045.x","volume":"17","author":"C Colosimo","year":"2010","unstructured":"Colosimo C, Suppa A, Fabbrini G, Bologna M, Berardelli A (2010) Craniocervical dystonia: clinical and pathophysiological features. Eur J Neurol 17(Suppl 1):15\u201321","journal-title":"Eur J Neurol"},{"key":"9314_CR30","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1212\/01.wnl.0000345010.98495.fc","volume":"72","author":"A Curr\u00e0","year":"2009","unstructured":"Curr\u00e0 A, Berardelli A (2009) Do the unintended actions of botulinum toxin at distant sites have clinical implications? Neurology 72:1095\u20131099","journal-title":"Neurology"},{"key":"9314_CR31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jvoice.2000.11.001","volume":"18","author":"FJ Damrose","year":"2004","unstructured":"Damrose FJ, Goldman NS, Groessl EJ, Orloff LA (2004) The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia. J Voice 18:415\u2013422","journal-title":"J Voice"},{"key":"9314_CR32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/archneur.59.3.418","volume":"59","author":"G Defazio","year":"2002","unstructured":"Defazio G, Abbruzzese G, Girlanda P et al (2002) Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 59:418\u2013420","journal-title":"Arch Neurol"},{"key":"9314_CR33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000067023","volume":"49","author":"D Dressler","year":"2003","unstructured":"Dressler D, Benecke R (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49:34\u201338","journal-title":"Eur Neurol"},{"key":"9314_CR34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1331.2006.01439.x","volume":"13","author":"D Dressler","year":"2006","unstructured":"Dressler D, Hallett M (2006) Immunological aspects of Botox, Dysport and Myobloc\/Neurobloc. Eur J Neurol 13:11\u201315","journal-title":"Eur J Neurol"},{"key":"9314_CR35","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000047963","volume":"47","author":"D Dressler","year":"2002","unstructured":"Dressler D, Munchau A, Bhatia KP, Quinn NP, Bigalke H (2002) Antibody induced botulinum-toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur Neurol 47:118\u2013121","journal-title":"Eur Neurol"},{"key":"9314_CR36","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00415-003-1129-6","volume":"250","author":"D Dressler","year":"2003","unstructured":"Dressler D, Bigalke H, Beneche R (2003) Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol 250:967\u2013969","journal-title":"J Neurol"},{"key":"9314_CR37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0039-6257(97)81995-9","volume":"41","author":"JJ Dutton","year":"1996","unstructured":"Dutton JJ (1996) Botulinum-A toxin in the treatment of craniocervical muscle spasms: short-and long-term, local and systemic effects. Surv Ophthalmol 41:51\u201365","journal-title":"Surv Ophthalmol"},{"key":"9314_CR38","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0161-6420(88)32977-5","volume":"95","author":"JJ Dutton","year":"1988","unstructured":"Dutton JJ, Buckley EG (1988) Long-term results and complications of botulinum toxin A in the treatment of blepharospasm. Ophtalmology 95:1529\u20131534","journal-title":"Ophtalmology"},{"key":"9314_CR39","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1002\/mds.20010","volume":"19","author":"R Eleopra","year":"2004","unstructured":"Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C (2004) Different types of botulinum toxin in humans. Mov Disord 19:S53\u2013S59","journal-title":"Mov Disord"},{"key":"9314_CR40","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0161-6420(87)33338-X","volume":"17","author":"PF Engstrom","year":"1987","unstructured":"Engstrom PF, Arnoult JB, Mazow ML et al (1987) Effectiveness of botulinum toxin therapy for essential blepharospasm. Ophtalmology 17:971\u2013975","journal-title":"Ophtalmology"},{"key":"9314_CR41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/mds.22983","volume":"25","author":"G Fabbrini","year":"2010","unstructured":"Fabbrini G, Berardelli I, Moretti G et al (2010) Psychiatric disorders in adult-onset focal dystonia: a case\u2013control study. Mov Disord 25:459\u2013465","journal-title":"Mov Disord"},{"key":"9314_CR42","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/00016489309135834","volume":"113","author":"GM Filippi","year":"1993","unstructured":"Filippi GM, Errico P, Santarelli R et al (1993) Botulinum A toxin effects o rat jaw muscle spindles. Acta Otolaryngol 113:400\u2013404","journal-title":"Acta Otolaryngol"},{"key":"9314_CR43","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00415-010-5880-1","volume":"258","author":"PJ Garcia Ruiz","year":"2011","unstructured":"Garcia Ruiz PJ, Martinez Castrillo JC, Burguera JA et al (2011) Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study. J Neurol 258:1055\u20131057","journal-title":"J Neurol"},{"key":"9314_CR44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/1531-8249(200007)48:1<20::AID-ANA5>3.0.CO;2-U","volume":"48","author":"F Giglio","year":"2000","unstructured":"Giglio F, Curra A, Lorenzano C, Modugno N, Manfredi M, Berardelli A (2000) Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann Neurol 48:20\u201326","journal-title":"Ann Neurol"},{"key":"9314_CR45","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1017\/S0317167100010817","volume":"37","author":"HS Gill","year":"2010","unstructured":"Gill HS, Kraft SP (2010) Long-term efficacy of botulinum a toxin for blepharospasmand hemifacial spasm. Can J Neurol Sci 37:631\u2013636","journal-title":"Can J Neurol Sci"},{"issue":"9 Suppl 2","key":"9314_CR46","first-page":"A88","volume":"74","author":"S Grafe","year":"2010","unstructured":"Grafe S, Hanschmann A (2010) Safety and efficacy of repeated NT 201 (botulinum neurotoxin type A free from complexing proteins) injections of patients with cervical dystonia: a first long-term safety analysis. Neurology 74(9 Suppl 2):A88","journal-title":"Neurology"},{"key":"9314_CR47","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/jnnp.51.6.767","volume":"51","author":"F Grandas","year":"1988","unstructured":"Grandas F, Elston J, Quinn N, Marsden CD (1988) Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 51:767\u2013772","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9314_CR48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","volume":"9","author":"P Greene","year":"1994","unstructured":"Greene P, Fahn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9:213\u2013217","journal-title":"Mov Disord"},{"key":"9314_CR49","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/mds.870130613","volume":"13","author":"CM Gudex","year":"1998","unstructured":"Gudex CM, Hawthorne MR, Butler AG, Duffey P (1998) Effect of dystonia and botulinum toxin treatment on health-related quality of life. Mov Disord 13:941\u2013946","journal-title":"Mov Disord"},{"key":"9314_CR50","first-page":"93","volume-title":"Therapy with botulinum toxin","author":"CL Hatheway","year":"1994","unstructured":"Hatheway CL, Dang C (1994) Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M (eds) Therapy with botulinum toxin. Marcel Dekker, New York, pp 93\u2013108"},{"key":"9314_CR51","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10659","volume":"19","author":"P Haussermann","year":"2004","unstructured":"Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A (2004) Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 19:303\u2013308","journal-title":"Mov Disord"},{"key":"9314_CR52","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jnnp.71.2.193","volume":"71","author":"R Hilker","year":"2001","unstructured":"Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J (2001) Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry 71:193\u2013199","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9314_CR53","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/000348940711601204","volume":"116","author":"PK Holden","year":"2007","unstructured":"Holden PK, Vokes DE, Taylor MB, Till JA, Crumley RL (2007) Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 116:891\u2013896","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"9314_CR54","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/mds.10252","volume":"17","author":"GYR Hsiung","year":"2002","unstructured":"Hsiung GYR, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O (2002) Long-term efficacy of botulinum toxin A in treatment of various Movement Disorders over a 10-year period. Mov Disord 17:1288\u20131293","journal-title":"Mov Disord"},{"key":"9314_CR55","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1002\/mds.20024","volume":"19","author":"J Jankovic","year":"2004","unstructured":"Jankovic J (2004a) Treatment of cervical dystonia with botulinum toxin. Mov Disord 19:S109\u2013S115","journal-title":"Mov Disord"},{"key":"9314_CR56","doi-asserted-by":"crossref","first-page":"951b","DOI":"10.1136\/jnnp.2003.034702","volume":"75","author":"J Jankovic","year":"2004","unstructured":"Jankovic J (2004b) Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 75:951b\u2013957b","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9314_CR57","first-page":"371","volume":"16","author":"J Jankovic","year":"1984","unstructured":"Jankovic J, Orman J (1984) Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol 16:371\u2013376","journal-title":"Ann Ophthalmol"},{"key":"9314_CR58","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","volume":"45","author":"J Jankovic","year":"1995","unstructured":"Jankovic J, Schwartz K (1995) Resistance and immunoresistance to botulinum toxin injections. Neurology 45:1743\u20131746","journal-title":"Neurology"},{"key":"9314_CR59","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","volume":"60","author":"J Jankovic","year":"2003","unstructured":"Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60:1186\u20131188","journal-title":"Neurology"},{"key":"9314_CR60","first-page":"837","volume":"139","author":"SP Kraft","year":"1988","unstructured":"Kraft SP, Lang AE (1988) Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin. CMAJ 139:837\u2013844","journal-title":"CMAJ"},{"key":"9314_CR61","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1212\/WNL.38.4.530","volume":"38","author":"DH Lowenstein","year":"1988","unstructured":"Lowenstein DH, Aminoff MJ (1988) The clinical course of spasmodic torticollis. Neurology 38:530\u2013532","journal-title":"Neurology"},{"key":"9314_CR62","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.parkreldis.2009.06.004","volume":"16","author":"FM Maia","year":"2010","unstructured":"Maia FM, Kanashiro AK, Chien HF, Goncalves LR, Barbosa ER (2010) Clinical changes of cervical dystonia pattern in long-term botulinum toxin treated patients. Parkinsonism Relat Disord 16:8\u201311","journal-title":"Parkinsonism Relat Disord"},{"key":"9314_CR63","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/mds.20376","volume":"20","author":"NI Mejia","year":"2005","unstructured":"Mejia NI, Young KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety and immunogenicity. Mov Disord 20:592\u2013597","journal-title":"Mov Disord"},{"key":"9314_CR64","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/(SICI)1097-4598(199812)21:12<1701::AID-MUS12>3.0.CO;2-K","volume":"21","author":"N Modugno","year":"1998","unstructured":"Modugno N, Priori A, Berardelli A et al (1998) Botulium toxin restores presynaptic inhibition of group la afferents in patients with essential tremor. Muscle Nerve 21:1701\u20131705","journal-title":"Muscle Nerve"},{"key":"9314_CR65","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1179\/174313209X405137","volume":"31","author":"B Mohammadi","year":"2009","unstructured":"Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K (2009) A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 31:463\u2013466","journal-title":"Neurol Res"},{"key":"9314_CR66","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s00415-002-0733-1","volume":"249","author":"J M\u00fcller","year":"2002","unstructured":"M\u00fcller J, Kemmler G, Wissel J et al (2002) The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 249:842\u2013846","journal-title":"J Neurol"},{"key":"9314_CR67","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1185\/030079904125003962","volume":"20","author":"M Naumann","year":"2004","unstructured":"Naumann M, Jankovic J (2004) Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 20:981\u2013990","journal-title":"Curr Med Res Opin"},{"key":"9314_CR68","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/MLG.0b013e31815e8be0","volume":"118","author":"RC Paniello","year":"2008","unstructured":"Paniello RC, Barlow J, Serna JS (2008) Longitudinal follow-up of adductor spasmodic dysphonia patients after botulinum toxin injection: quality of life results. Laryngoscope 118:564\u2013568","journal-title":"Laryngoscope"},{"key":"9314_CR69","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/s-2007-971171","volume":"27","author":"S Papapetropoulos","year":"2007","unstructured":"Papapetropoulos S, Singer C (2007) Botulinum toxin in movement disorders. Semin Neurol 27:183\u2013194","journal-title":"Semin Neurol"},{"key":"9314_CR71","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/brain\/118.3.801","volume":"118","author":"A Priori","year":"1995","unstructured":"Priori A, Berardelli A, Mercuri B, Manfredi M (1995) Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles. Brain 118:801\u2013807","journal-title":"Brain"},{"key":"9314_CR72","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1600-0404.2004.00357.x","volume":"111","author":"J Reimer","year":"2005","unstructured":"Reimer J, Gilg K, Karow A, Esser J, Franke GH (2005) Health-related quality of life in blepharospasm or hemifacial spasm. Acta Neurol Scand 111:64\u201370","journal-title":"Acta Neurol Scand"},{"key":"9314_CR73","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/(SICI)1097-4598(199604)19:4<488::AID-MUS9>3.0.CO;2-8","volume":"19","author":"RL Rosales","year":"1996","unstructured":"Rosales RL, Arimura K, Takenaga S et al (1996) Extrafusal and intrafusal muscle effects in experimental botulinum toxin injection. Muscle Nerve 19:488\u2013496","journal-title":"Muscle Nerve"},{"key":"9314_CR74","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0041-0101(00)00163-X","volume":"39","author":"O Rossetto","year":"2001","unstructured":"Rossetto O, Seveso M, Caccin P, Schiavo G, Montecucco C (2001) Tetanus and botulinum neurotoxins: turning bad guys into good by research. Toxicon 39:27\u201341","journal-title":"Toxicon"},{"key":"9314_CR75","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1002\/mds.20066","volume":"19","author":"C Sampaio","year":"2004","unstructured":"Sampaio C, Costa J, Ferreira JJ (2004) Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 19:S129\u2013S136","journal-title":"Mov Disord"},{"key":"9314_CR76","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archopht.1985.01050030043017","volume":"103","author":"AB Scott","year":"1985","unstructured":"Scott AB, Kennedy RA, Stubbs HHA (1985) Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 103:347\u2013350","journal-title":"Arch Ophthalmol"},{"key":"9314_CR77","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","volume":"70","author":"DM Simpson","year":"2008","unstructured":"Simpson DM, Blitzer A, Brashear A (2008) Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 70:1699\u20131706","journal-title":"Neurology"},{"key":"9314_CR78","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-1331.2004.01053.x","volume":"12","author":"IM Skogseid","year":"2005","unstructured":"Skogseid IM, Kerty E (2005) The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 12:163\u2013170","journal-title":"Eur J Neurol"},{"key":"9314_CR79","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1468-1331.2007.01922.x","volume":"14","author":"IM Skogseid","year":"2007","unstructured":"Skogseid IM, Malt UF, Roislien J, Kerty E (2007) Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. Eur J Neurol 14:1129\u20131137","journal-title":"Eur J Neurol"},{"key":"9314_CR80","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1212\/WNL.53.9.2102","volume":"53","author":"EK Tan","year":"1999","unstructured":"Tan EK, Jankovic J (1999) Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 53:2102\u20132107","journal-title":"Neurology"},{"key":"9314_CR81","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00415-008-0753-6","volume":"255","author":"D Tiple","year":"2008","unstructured":"Tiple D, Strano S, Colosimo C et al (2008) Autonomic cardiovascular function and baroreflex sensitivity in patients with cervical dystonia receiving treatment with botulinum toxin type A. J Neurol 255:843\u2013847","journal-title":"J Neurol"},{"key":"9314_CR82","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/mds.20801","volume":"21","author":"C Trompetto","year":"2006","unstructured":"Trompetto C, Curr\u00e0 A, Buccolieri A, Suppa A, Abbruzzese G, Berardelli A (2006) Botulinum toxin changes intrafusal feedback in dystonia: a study with the tonic vibration reflex. Mov Disord 21:777\u2013782","journal-title":"Mov Disord"},{"key":"9314_CR83","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","volume":"16","author":"D Truong","year":"2010","unstructured":"Truong D, Brodsky M, Lew M et al (2010) Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 16:316\u2013323","journal-title":"Parkinsonism Relat Disord"},{"key":"9314_CR84","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/mus.880180708","volume":"18","author":"P Van den Bergh","year":"1995","unstructured":"Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre EC (1995) Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve 18:720\u2013729","journal-title":"Muscle Nerve"},{"key":"9314_CR85","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1002\/mds.10142","volume":"17","author":"JL Vitek","year":"2002","unstructured":"Vitek JL (2002) Pathophysiology of dystonia: a neuronal model. Mov Disord 17:S49\u2013S62","journal-title":"Mov Disord"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-012-9314-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12640-012-9314-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-012-9314-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T23:34:53Z","timestamp":1561332893000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12640-012-9314-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,23]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["9314"],"URL":"https:\/\/doi.org\/10.1007\/s12640-012-9314-y","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"value":"1029-8428","type":"print"},{"value":"1476-3524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,23]]}}}